BioLine Rx
🇮🇱Israel
- Country
- 🇮🇱Israel
- Ownership
- Public
- Established
- 2003-01-01
- Employees
- 79
- Market Cap
- $59.2M
- Website
- http://www.biolinerx.com
- Introduction
BioLineRx Ltd. is a clinical stage biopharmaceutical company, which engages in the research and development of treatments that focus on cancer. Its product pipeline includes Motaxafortide (BL-8040), which is used for stem-cell mobilization, solid tumors, and acute myeloid lukemia; and AGI-134, which is an immunotherapy treatment used for multiple solid tumors. The company was founded in 2003 and is headquartered in Modi'in, Israel.
Genentech Advances RO-7759065 Development for Metastatic Solid Tumors
• Genentech USA is developing RO-7759065, a novel parenteral treatment targeting metastatic solid tumors, expanding their robust oncology pipeline.
• The drug candidate is undergoing clinical evaluation with GlobalData tracking its phase transition and likelihood of approval based on 18 years of historical drug development data.
• Genentech, a Roche subsidiary, brings significant expertise in oncology drug development, supported by partnerships with BioLineRx, Charles River Laboratories, and Amunix.
BioLineRx's APHEXDA Gains Momentum in Stem Cell Mobilization for Multiple Myeloma
• BioLineRx's APHEXDA (motixafortide) receives FDA approval for stem cell mobilization in multiple myeloma patients, marking a significant advancement in over a decade.
• Commercial launch of APHEXDA in the U.S. is underway, with positive feedback from transplant centers indicating it addresses a critical unmet need for effective mobilization.
• Clinical trials explore motixafortide's potential in pancreatic cancer and sickle cell disease, demonstrating versatility across hematological and solid tumor cancers.
• Gloria Biosciences partners with BioLineRx for development and commercialization of motixafortide in Asia, including a bridging study in China for stem cell mobilization.
Breakthroughs in Biotech: Promising Developments in Diabetes, Cancer, and Lymphoma Treatments
Recent advancements in the biotech sector highlight significant progress in treatments for diabetes, breast cancer, multiple myeloma, and T cell lymphoma, with several companies receiving FDA approvals or making notable strides in clinical trials.
© Copyright 2025. All Rights Reserved by MedPath